Nuvalent, Inc. (NUVL) Thursday reported a wider net loss for the first quarter compared to the prior year.
The Cambridge, Massachusetts-based clinical-stage biopharmaceutical company reported loss of $44.48 million for the first quarter, compared to $25.19 million in the previous year.
On a per-share basis, loss was $0.69 per share, wider than $0.44 last year.
On average, 9 analysts polled by Thomson Reuters expected the company to report loss of $0.68 per share. Analysts estimates usually exclude special items.
James Porter, CEO of Nuvalent said, "We expect to share clinical updates from our parallel lead programs for ROS1-positive and ALK-positive NSCLC at a medical meeting in the second half of the year and are on-track to dose the first patient in our HER2 program this year."
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.